{"title":"Much anticipated FDA decision about psychedelics for PTSD ends with denial","authors":"Valerie A. Canady","doi":"10.1002/mhw.34150","DOIUrl":null,"url":null,"abstract":"<p>In a closely watched decision involving the use of psychedelic treatment and therapy to treat post-traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)-assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA-assisted therapy to its drug maker, Lykos Therapeutics.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In a closely watched decision involving the use of psychedelic treatment and therapy to treat post-traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)-assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA-assisted therapy to its drug maker, Lykos Therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
